Skip to main content
Clinical Trials/NCT02349620
NCT02349620
Unknown
Phase 2

Platelet-rich Factot in Implant Dentistry

Reza Tabrizi1 site in 1 country30 target enrollmentSeptember 2014

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Osseointegrated Dental Implantation
Sponsor
Reza Tabrizi
Enrollment
30
Locations
1
Primary Endpoint
implant loss
Last Updated
11 years ago

Overview

Brief Summary

The main objective of this clinical trial study is to consider the effect of Platelet-Rich-Factor (PRF) on implant stability and marginal bone resorption around dental implants.

Detailed Description

Dental implants were placed in 30 subjects who have 1 or 2 missing teeth in both side of posterior mandible. Implants with a length of 11.5 and a diameter of 4.5 mm will be inserted in both sides. In one side PRF will be instilled after surface treatment with PRF before implant placement, while no PRF was added in other side to serve as control group. All implants will be followed with stability measurement by means of resonance frequency analysis at baseline, and every two weeks up to 3 months. Bone height was measured on medial \& distal side on standardized IOPA x-rays.

Registry
clinicaltrials.gov
Start Date
September 2014
End Date
October 2015
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Reza Tabrizi
Responsible Party
Sponsor Investigator
Principal Investigator

Reza Tabrizi

Assistant professor of shahid beheshti university of medical sciences

Shiraz University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • patients who have 1 or 2 missing teeth in both side of posterior mandible
  • adequate bone quantity and quality at the implant site
  • the implant sites with at least 3 months of healing after extraction,
  • patients well motivated for implant therapy and maintaining good oral hygiene
  • the implant sites with width and length to installation of an implant of 4.5 mm x 11.5 mm.
  • Patients who gave written informed consent

Exclusion Criteria

  • • medically compromised or patients taking any immunosuppressive drugs which may complicate the treatment outcome
  • infection around the implant site
  • history of bruxism/parafunctional habits
  • patients with history of any bleeding disorder or on anti-coagulant therapy.
  • pregnant patients

Outcomes

Primary Outcomes

implant loss

Time Frame: 6 months

During the osseointegration, if the implant lose his stability and if the patient have pain, the implant will be removed and the implant will be considered lost

Secondary Outcomes

  • ISQ analysis(3 months)
  • bone height (mm)(6 months)

Study Sites (1)

Loading locations...

Similar Trials